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Novel use of endoluminal repair as prophylaxis of
aortic rupture secondary to radiotherapy for lung
cancer
Camus Nimmo, MB, BS,a Oliver Lyons, MRCS,a Rachel Clough, MRCS,a David Landau, FRCR,b
Tom Routledge, FRCS,c and Peter Taylor, FRCS,a London, United Kingdom
Non-small-cell lung cancer (NSCLC) invading the aorta is staged as T4. Only 9% of T4 tumors are resected; the alternative
is chemoradiotherapy, but for peri-aortic NSCLC, radiation damage to the aortic wall can induce fatal rupture. We report
the case of a 76 year-old man with a 3-cm left lower lobe NSCLC clearly invading the aortic wall. A thoracic stent graft
was inserted prophylactically to prevent aortic rupture. He then received 64 Gy radiotherapy in 32 fractions, resulting in
tumor shrinkage. Prophylactic aortic endografting, a less invasive treatment than open surgery, may enable high dose
irradiation of the aortic wall. ( J Vasc Surg 2011;54:1795-7.)
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wThe cornerstone of management of non-small-cell lung
cancer (NSCLC) with limited nodal spread (N0-1) and
without metastases (M0) is surgical resection of the tumor,
usually by lobectomy. Invasion of local structures such as
the vertebral body or aorta (T4 disease) has historically been
thought to render a tumor unresectable.1,2 It has been
recognized that limited (N0-1) spread of T4 disease may be
a marker of reduced biological propensity to metastasize.
Good survival is possible in selected patients who are fit for
radical resection.3 Invasion of the aorta may be managed by
tube graft replacement of the affected segment alongside
the primary tumor, usually requiring aortic cross-clamping
and sometimes a passive shunt or partial cardiopulmonary
bypass. However, few patients are fit for this,4 and therefore
for node positive disease, the long-term prognosis is poor;
for most patients, palliative chemoradiotherapy is the only
option.3,5 This poses a particular problem for malignant
aortic invasion as major arterial rupture following radio-
therapy is well described for head and neck, esophageal, and
pelvic cancers.6-8
Radiotherapy causes arterial inflammation, thrombosis,
and vessel occlusion at lower doses (comparable to90 Gy
of 192Ir brachytherapy) and arterial rupture at high doses
(120 Gy of 192Ir brachytherapy).9 In addition, tumor
necrosis in the aortic wall, causing weakening and rupture,
has been reported.10 Endovascular stent graft repair of the
thoracic aorta is a minimally invasive technique that has
become the treatment of choice for thoracic aortic rup-
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doi:10.1016/j.jvs.2011.06.027ure.11 We present a novel indication to use this minimally
nvasive technique – the prophylaxis of aortic rupture sec-
ndary to both an invading lung carcinoma and the radio-
herapy used to treat it.
ASE REPORT
A 76-year-old man who suffered from hypertension and type 2
iabetes (both tablet-controlled) presented to his general physician
ith a persistent cough. He had a 100 pack-year smoking history. He
as investigated with plain chest radiography, followed by computed
omography (CT) and CT-guided biopsy, which identified a 3-cm
4N0M0NSCLCwith thoracic aortic wall invasion (Fig,A). Spirom-
try showed he had a forced expiratory volume in 1 second (FEV1) of
1% predicted and a transfer factor (TLCO) of 68% predicted. Com-
lete resection would require a left lower lobectomy and aortic recon-
truction with a patch or tube graft. Given the extent of invasion, the
ultidisciplinary lung cancer team recommended 64Gy of radiother-
py in 32 fractions over 6.5 weeks, in line with national guidelines.2
hemaximumaorticwall dosewas estimated to be 66Gy (Fig,B). To
revent aortic rupture secondary to radiotherapy-induced necrosis of
he invading tumor or aortic wall, prior to commencing radiotherapy
31 100-mmC-TAG/GORE endograft (W. L. Gore and Associ-
tes, Flagstaff, Ariz) was inserted into the thoracic aorta via femoral
rtery cut down under loco-regional anesthesia. The stent graft was
ositioned to exclude the portion of aorta affected by radiation and
umor invasion.
The procedure was uncomplicated, and he was discharged
ome on the second postoperative day. Three months post-
ndograft insertion, he had successfully completed radiother-
py, complicated by only limited skin erythema and a persistent
ough. Follow-up positron emission tomography-CT scan 7
onths after radiotherapy completion showed good position of
he stent graft, some residual soft tissue thickening at the tumor
ite most likely to represent inflammation (maximum standard-
zed uptake value fell from 9.5 before radiotherapy to 2.9), and
adiotherapy-induced interstitial lung changes. There was
o evidence of metastasis. These findings were consistent
ith repeat CT scan 8 months after radiotherapy completion
Fig, C).
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Resection is not currently recommended for T4
NSCLC.2 Although in small series of selected patients
resection of T4N0-1 NSCLC has produced promising re-
sults, in practice only 9% of patients with T4 tumors un-
dergo resection, leaving radiotherapy (with chemotherapy)
as the major treatment option.4 In highly selected patients,
the operative mortality for resection of NSCLC with aortic
invasion is 0% to 13%, but the 5-year survival for N0-2
disease ranges from 100% (N0), to 37% (N1) and 0% (N2)
(5,12, for review, see 3). The operation itself is suggested to
be responsible for 50% of postoperative mortality and 80%
of morbidity.5 Although thoracic aortic stent grafts have
recently been used to enable surgical resection of the aorta
in lung tumors with aortic invasion,13 the morbidity of the
pulmonary resection is still incurred.
The great vessels are generally thought to be relatively
resistant to the effects of standard radiotherapy. Reports of
aortic wall defects with conventional fractionation (daily
doses of 1.8-2.67 Gy to a total dose of 40-66 Gy) are rare.
Radiotherapy-induced arterial rupture is most frequently
reported in the carotid arteries, followed by the aorta and
then femoral arteries.7 Aortic rupture is most commonly
reported following radiotherapy for esophageal cancer,6,7
where the use of metallic stents could lead to erosion of the
esophageal and aortic walls. The data suggest an association
between radiation dose and incidence of massive hemor-
rhage, with a notable increase in incidence at higher doses.6
Recently, brachytherapy has been used as an adjunct to
sublobar resection of NSCLC through implantation of
125I-impregnated vicryl mesh adjacent to resected lung.14
In a subgroup of 29 patients, the mesh had over 50%
contact with the aorta, delivering a mean total dose of 114
Gy (range, 85-120 Gy) over the life of the implant (half-life
60 days;98% of radiation delivered within 1 year). There
was one rupture (1/29, 3.4%) in a patient who received an
additional 45 Gy of external beam radiotherapy overlap-
ping the brachytherapy area.
High dose stereotactic radiotherapy is being increas-
ingly used in patients with stage I NSCLC not fit for
surgery with curative intent. Recent results show better
local tumor control at 3 years (97.6%) compared with
Fig. A, Computed tomography (CT) slice demonstrati
configuration and dose distribution of the radical radiot
isodose. C, CT slice 8 months after prophylactic reinforc
with 6.5 weeks of 64 Gy radiotherapy.standard radiotherapy using a dose of 60 to 66 Gy.15 Whileanaging to avoid some of the risks of conventional radio-
herapy by focusing radiation on the target area, far higher
aily doses up to 20 Gy are used, and the immediate tumor
urroundings are subjected to a greater proportion of this
ose, putting them at a higher risk of damage.16
The mortality from a ruptured thoracic aorta (in aneu-
ysmal disease) is 97% to 100%; the thoracic cavity accom-
odates a large volume of blood, and few patients survive
o reach the emergency department.17 Open repair of
horacic aortic aneurysm rupture has a 30-day mortality of
6%. Thoracic aortic stent grafts are proven to exclude a
uptured segment of aorta from the circulation and are
ommonly inserted under loco-regional anesthesia, avoid-
ng the need for thoracotomy and aortic cross-clamping.
hey have reduced 30-day mortality to 19% with fewer
omplications.11 Stent grafting is equally effective yet safer
han elective open repair for aneurysmal disease. The mor-
ality for elective thoracic aneurysm exclusion is approxi-
ately 2.5%.18Major complications are neurological (para-
legia and stroke, 2.5%), renal failure (6.1%), and infection
4.3%).19 The incidence of complications after intervention
n an intrinsically healthy aorta is unknown. There are no
arge studies on the effects of radiotherapy to polytetrafluo-
oethlyene grafts in humans.
ONCLUSION
Endografting of aortic wall invaded by tumor can be
sed to enable resection of the invaded segment. In
atients unsuitable for surgical resection, it reduces the
isk of rupture secondary to radiotherapy-induced tumor
r mural necrosis, and may make aortic irradiation with
igh dose (including stereotactic) radiotherapy safer.
arge series will be required to demonstrate the out-
omes of this technique.
The authors would like to acknowledge Rebecca Lynn
or providing the radiotherapy planning images.
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